Overview

68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the potential of the 68Ga-NODAGA-RGD for the evaluation of neoangiogenesis in patients followed for a neoplastic pathology and for whom a18F-FDG (or 18F-FET for gliomas) is indicated for initial extension evaluation or suspicion of recurrent tumor.
Phase:
Phase 1
Details
Lead Sponsor:
University of Lausanne Hospitals
Collaborator:
George Coukos, MD PhD, Head of oncology
Treatments:
Fluorodeoxyglucose F18